Drug

Digoxin

In clinical development

ClassSodium/potassium-transporting ATPase inhibitorEmerging researchLate-stage development

Also known as Cardoxin, Digitek, Digossina, Lanoxicaps+5 more

Cardoxin, Digitek, Digossina, Lanoxicaps, Lanoxin, Digox, Digoxina, Digoxine, Digoxinum.

RxNorm3407 ChEMBLCHEMBL1751 ATCC01AA05UNII73K4184T59

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects

Clinical trial2026-07-20Status changed to Active, not recruiting · ClinicalTrials.gov

Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma

Clinical trial2026-07-07Results expected Q1 2027 · ClinicalTrials.gov

A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants

Clinical trial2026-07-06Results expected Q4 2026 · ClinicalTrials.gov

A Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants

Clinical trial2026-06-25Primary completion · ClinicalTrials.gov

Evaluation of Digoxin Therapy in Patients With Heart Failure After Acute Decompensation

Clinical trial2026-06-02Results expected Q4 2027 · ClinicalTrials.gov

Clinical Trial of Oral Digoxin In NASH (CODIN)

Clinical trial2026-05-26Results expected Q1 2029 · ClinicalTrials.gov

A Drug-Drug Interaction Study to Assess the Effect of Orforglipron on the Pharmacokinetics of Digoxin, Simvastatin, Rosuvastatin, Acetaminophen, and Midazolam in Healthy Overweight and Obese Participants

Clinical trial2026-05-22Results posted · ClinicalTrials.gov

A Study to Investigate the Effects of Multiple Doses of BI 425809 on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin and Omeprazole) and a P Glycoprotein Substrate (Digoxin) Administered Orally in an Open-label, One-sequence Trial in Healthy Male Subjects

Clinical trial2026-04-15Results posted · ClinicalTrials.gov

A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Influence of HDM1005 on Gastric Emptying and Drug-Drug Interaction of HDM1005 and Metformin, Atorvastatin, Warfarin, and Digoxin in Overweight/Obese Adult Chinese Subjects

Clinical trial2026-03-30Results expected Q4 2026 · ClinicalTrials.gov

Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Clinical trial2026-03-19Completed · ClinicalTrials.gov

Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.

Research2024-01-25Drug safety

Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.

Research2002-12-01JAMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Digoxin

Aliases & brands

CardoxinDigitekDigossinaLanoxicapsLanoxinDigoxDigoxinaDigoxineDigoxinum

RxNorm CUI

3407

ChEMBL ID

CHEMBL1751

ATC codes

C01AA05

UNII

73K4184T59

Primary mechanism

Sodium/potassium-transporting ATPase inhibitor

Pharmacology & targets

8 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Sodium/potassium-transporting ATPase subunit alpha-1

ATP1A1 · P05023